The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Despite solid data, the lack of high-value indications and no unique platform makes Nuvalent's valuation seem inflated; I ...

Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have received nationwide Medicare coverage ...

The big question is whether it can displace Tagrisso (osimertinib), like Lazcluze a third-generation EGFR TKI and AZ's top-selling ... with 80-85% of them having NSCLC. Of these, around 70% ...

The US regulator has cleared the tyrosine kinase inhibitor (TKI) as a second-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumours have EGFR ...

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care Flood exposure was more strongly associated with ...

SARAJEVO, April 4 (Reuters) - The government of Bosnia's autonomous Serb Republic declared a senior German foreign ministry official persona non grata on Friday and barred her from visiting the ...

During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by ...

Have you outgrown any of the people in your life, Cancer? As Venus retrograde in your wide-ranging ninth house links with progressive Uranus in your humanity zone today, you could discover that a ...

Aumolertinib is a third generation EGFR tyrosine kinase inhibitors, approved for use in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). Here, the authors report a phase 2 ...